{"id":"W4407699539","doi":"10.1200/jco.2025.43.5_suppl.662","title":"A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with <i>FGFR3</i> alterations: Initial results from FORAGER-1.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Medicine; Gene isoform; Cancer research; Internal medicine; Pathology; Oncology; Biochemistry; Gene; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00176775,0.002243665,0.001873974,0.0004285572,0.0005729456,0.001101493,0.0009742531,0.001498729,0.00434608],"category_scores_gemma":[0.0008091439,0.0007915832,0.001371937,0.0003989554,0.0009297503,0.001027441,0.0005142328,0.003349202,0.001606063],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001304079,"about_ca_system_score_gemma":0.001760976,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00147017,"about_ca_topic_score_gemma":0.003666836,"domain_scores_codex":[0.9994966,0.0001997799,0.00002325915,0.0000889923,0.00005555237,0.0001359111],"domain_scores_gemma":[0.9993095,0.00009608468,0.0001103915,0.00006720854,0.00005659478,0.0003601841],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4356989,0.1799666,0.01234546,0.001715107,0.002001191,0.001472047,0.000967467,0.007203821,0.1635362,0.0006981587,0.0247211,0.1696739],"study_design_scores_gemma":[0.2929599,0.6540841,0.02067851,0.00006694343,0.0006273577,0.001304171,0.0001271793,0.00191919,0.01625457,0.0004761688,0.01143337,0.00006852225],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9789782,0.003010178,0.001926858,0.0007161591,0.000145901,0.006364867,0.005489168,0.0002419673,0.003126714],"genre_scores_gemma":[0.9618817,0.003304184,0.004821952,0.001839106,0.0001985624,0.005773365,0.01358194,0.0001395657,0.008459494],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00434608,"threshold_uncertainty_score":0.01453906,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04495718704566696,"score_gpt":0.4567314972121554,"score_spread":0.4117743101664884,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}